Inventiva is a French biopharmaceutical company specializing in the research and development of innovative treatments, primarily for non-alcoholic steatohepatitis (NASH) and other fibrotic diseases. Founded in 2012 following a spin-off from Abbott's research division, the company leverages its expertise in nuclear receptors, transcription factors, and epigenetic modulation. Its lead drug candidate, lanifibranor, is in late-stage clinical trials for the treatment of NASH. Inventiva is publicly traded on the Euronext Paris stock exchange and on the NASDAQ Global Market.

Founded in

India